An Open-label, Prospective, Single-arm Study Assessing the Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Latest Information Update: 05 Nov 2026
At a glance
- Drugs Rozanolixizumab (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors UCB Biopharma
Most Recent Events
- 29 Oct 2026 Status changed from recruiting to active, no longer recruiting.
- 19 Dec 2025 Status changed from not yet recruiting to recruiting.
- 02 Dec 2025 New trial record